Drug Trial Radar · NCT00942305
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Last checked: Nov 19, 2026Latest source record: Jul 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
239
Actual
Start
Oct 2009
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Jul 20, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks. Dosing was initiated immediately following engraftment (between Days 14-30 post-transplant) to prevent/control cytomegalovirus (CMV) infection or prevent disease in R+ hematopoietic stem cell transplant (HCT) recipients.
Conditions
- Cytomegalovirus Infection
Interventions
BrincidofovirDrug
Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
PlaceboDrug
Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant. Matching placebo administered for each cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinically Significant CMV InfectionTime frame: Randomization to Week 8 post-treatment (~19 weeks)
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama
Moores UCSD Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
University of Colorado Denver
Aurora, Colorado
Winship Cancer Institute at Emory University
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Brigham and Womens Hospital, Division of Infectious Disease
Boston, Massachusetts
University of Michigan Medical School
Ann Arbor, Michigan
Harper University Hospital
Detroit, Michigan
University of Minnesota Medical Center
Minneapolis, Minnesota
Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Mt. Sinai School of Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Montefiore Medical Center Oncology
The Bronx, New York
UNC Health Care Center
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
The Cleveland Clinic
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Baylor University Medical Center
Dallas, Texas
UT Southwestern Medical Center at Dallas
Dallas, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists - Intermountain Healthcare
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.